Infinity Announces Clinical Data to Be Presented at ASCO and ICML
May 15, 2013| CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 15, 2013--
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that Phase
1 clinical data for IPI-145, its potent, oral inhibitor of
phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, will be presented
at the 49th Annual Meeting of the American Society of
Clinical Oncology (ASCO), which is being held from May 31 through June 4
in Chicago, Ill., and the 12th International Conference on
Malignant... |
|
Infinity to Present at the UBS Global Healthcare Conference
May 14, 2013| CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 14, 2013--
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the
UBS Global Healthcare Conference on May 21, 2013, at 12:30 p.m. ET in
New York.
A live webcast of Infinity's presentation will be accessible on the
“investors/media” section of the company's website, www.infi.com,
and will be available for 30 days following the event.
About Infinity Pharmaceuticals, Inc.
... |
|
Infinity Reports First Quarter 2013 Financial Results and Provides Company Update
May 07, 2013| – Phase 1 Clinical Data for IPI-145 to be Presented at ASCO and the
International Conference on Malignant Lymphoma –
– IPI-145 Granted Orphan Drug Designation by FDA and EMA for the
Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
–
– The ASPIRA Trial, a Phase 2 Study Evaluating IPI-145 for the
Treatment of Rheumatoid Arthritis, Open for Enrollment –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 7, 2013--
... |
|
Infinity Announces the Date of Its First Quarter 2013 Financial Results Conference Call and Webcast
Apr 24, 2013| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 24, 2013--
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference
call on Tuesday, May 7, 2013, at 4:30 p.m. ET. During the call,
management will provide an update on Infinity's business and discuss the
company's first quarter 2013 financial results.
A live webcast of the conference call can be accessed in the
Investors/Media section of Infinity's website at www.infi.com.
To participate... |
|
Infinity to Present at the Needham 12th Annual Healthcare Conference
Apr 23, 2013| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 23, 2013--
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the
Needham 12th Annual Healthcare Conference on April 30, 2013,
at 4:20 p.m. ET in New York.
A live webcast of Infinity's presentation will be accessible on the
“investors/media” section of the company's website, www.infi.com,
and will be available for 30 days following the event.
About Infinity Pharmaceuticals, I... |
|
Infinity Announces Closing of Secondary Offering of Common Stock and Exercise of Over-Allotment Option
Apr 16, 2013| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 16, 2013--
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the
closing of an underwritten public offering of its common stock, at a
price of $40.00 per share, by existing shareholders Beacon Company and
Rosebay Medical Company L.P., including shares that were transferred to
Beacon and Rosebay by Purdue Pharma L.P., an associated company of
Beacon and Rosebay. The total number of shares of common stock... |
|
Infinity Announces Pricing of Secondary Offering of Common Stock
Apr 11, 2013| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 11, 2013--
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the
pricing of an underwritten public offering of its common stock by
existing shareholders Beacon Company and Rosebay Medical Company L.P.,
including shares that were transferred to Beacon and Rosebay by Purdue
Pharma L.P., an associated company of Beacon and Rosebay, at a public
offering price of $40.00 per share. The aggregate size of the o... |
|
Infinity Announces Proposed Secondary Offering of Common Stock
Apr 09, 2013| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 9, 2013--
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced an
underwritten public offering of its common stock by existing
stockholders Beacon Company and Rosebay Medical Company L.P., including
shares that will be transferred to Beacon and Rosebay by Purdue Pharma
L.P., an associated company of Beacon and Rosebay. The aggregate size of
the offering is 8,500,000 shares, with 4,250,000 shares of commo... |
|
Infinity to Present at the 25th Annual Roth Conference
Mar 11, 2013| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 11, 2013--
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the
25th Annual ROTH Conference on March 18, 2013, at 3:00 p.m.
PT (6:00 p.m. ET) in Laguna Nigel, CA.
A live webcast of Infinity's presentation will be accessible on the
“investors/media” section of the company's website, www.infi.com,
and will be available for 30 days following the event.
About Infinity Pharm... |
|
Infinity Provides Company Update and Reports Full-Year 2012 Financial Results
Mar 05, 2013|
– Cohort Expansions of Phase 1 Trial of IPI-145 in Patients with
Advanced Hematologic Malignancies Now Enrolling –
– Key Data Expected from PI3K and Hsp90 Programs in 2013 –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 5, 2013--
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) reported its full-year
2012 financial results and ongoing progress with IPI-145, its potent,
oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma,
... |
|
Infinity to Present at Upcoming Conferences
Feb 25, 2013| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 25, 2013--
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will present at the
following investor conferences:
Cowen
and Company 33rd Annual Health Care Conference, Boston, March 4,
2013, at 4:50 p.m. ET
Barclays
Global Healthcare Conference, Miami, March 12, 2013, at 9:30 a.m.
ET
Bernstein Emerging Biotech Conference 2013, Snowbir... |
|
Infinity Announces the Date of Its Full-Year 2012 Financial Results Conference Call and Webcast
Feb 19, 2013| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 19, 2013--
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference
call on Tuesday, March 5, 2013, at 4:30 p.m. ET. During the call,
management will provide an update on Infinity's business and discuss the
company's full-year 2012 financial results.
A live webcast of the conference call can be accessed in the
Investors/Media section of Infinity's website at www.infi.com.
To participa... |
|
Infinity to Participate in Three Conferences in February
Feb 06, 2013| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2013--
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be participating in
the following conferences in February 2013:
2013 Leerink Swann Healthcare Conference, New York, February 13, 2013,
at 9:00 a.m. ET
Citi 2013 Global Healthcare Conference, New York, February 25, 2013,
at 9:35 a.m. and 2:15 p.m. ET (panel discussions)
2013 RBC Capital M... |
|
Infinity Provides Key 2013 Goals and Financial Guidance
Jan 07, 2013|
– Additional Data from Phase 1 Trial of IPI-145 in Hematologic
Malignancies Anticipated in 2013 –
– Expands PI3K Franchise with New Product Candidate –
– Strong Financial Position with Cash Runway into 2015 –
– Company to Present at JPMorgan Annual Healthcare Conference at 10
a.m. PT –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 7, 2013--
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its
antic... |
|
